Recent News

• 01.09.2026 - Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update
• 11.05.2025 - Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.03.2025 - Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler
• 10.30.2025 - Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
• 10.27.2025 - Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Recent Filings

• 12.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.12.2025 - 3 Initial statement of beneficial ownership of securities
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 8-K Current report
• 11.05.2025 - EX-99.1 EX-99.1